Company intelligence / Profile preview

Nurami Medical

Ownership: Private
Development stage: Commercial

Overview

Nurami Medical has developed ArtiFascia®, the world’s first multilayer dural substitute for neurosurgical applications. The company’s products are based on proprietary electrospun nanofiber technology designed to mimic the extracellular matrix and promote rapid healing while providing a watertight seal. Their lead product has received FDA clearance and addresses complications such as cerebrospinal fluid leaks following brain surgery. The company continues to develop additional surgical sealants and grafts for broader soft tissue repair applications.

Therapeutic areas: OtherNeurology
Modalities: DeviceHydrogel-based drug delivery therapyNanofiber scaffold
Industry: Surgical Medical Devices

Drug pipeline

2 assets

ArtiFascia

Commercial

Indications: Dural repair, Cerebrospinal fluid leakage

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Nurami Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nurami Medical.

Explore the full profile